Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 10.49% is 159% above its 5-year average of -17.78%, near the high end of its 5-year range (-132.86%–34.42%).
2387.92% above its 12-month average of -0.46%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -11.02%.
EBITDA MARGIN
10.49%
EBITDA MARGIN AVG TTM
-0.46%
EBITDA MARGIN AVG 3Y
-0.11%
EBITDA MARGIN AVG 5Y
-17.78%
EBITDA MARGIN AVG 10Y
-53.45%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2387.92%
CURRENT VS 3Y AVG
+9703.66%
CURRENT VS 5Y AVG
+159.01%
CURRENT VS 10Y AVG
+119.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Akebia Therapeutics, Inc.
Market Cap
$236.20M
EBITDA Margin
10.49%
TTM Avg
-0.46%
3Y Avg
-0.11%
5Y Avg
-17.78%
Market Cap
$232.19M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$236.58M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
Market Cap
$238.61M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
Market Cap
$225.46M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$229.14M
EBITDA Margin
-43.93%
TTM Avg
-56.69%
3Y Avg
-115.93%
5Y Avg
-139.79%
Market Cap
$243.64M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $236.20M | 10.49% | -0.46% | -0.11% | -17.78% |
| High Tide Inc. (HITI)vs › | $237.27M | 1.66% | 3.74% | -1.53% | 0.81% |
| Galectin Therapeutics Inc. (GALT)vs › | $237.74M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $232.19M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| InflaRx N.V. (IFRX)vs › | $238.61M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Biodesix, Inc. (BDSX)vs › | $225.46M | -25.05% | -32.88% | -63.97% | -61.52% |
| MacroGenics, Inc. (MGNX)vs › | $229.14M | -43.93% | -56.69% | -115.93% | -139.79% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.64M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | 6.37% | -0.39% | -2.45% | 1.13% |
Gross Margin
79.5%
EBITDA Margin
10.5%
Operating Margin
9.9%
Net Margin
-13.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -11.02% |
| 2026-03-31 | -8.16% |
| 2025-12-31 | -14.29% |
| 2025-09-30 | 8.11% |
| 2025-06-30 | 23.06% |
| 2025-03-31 | 24.12% |
| 2024-12-31 | -10.67% |
| 2024-09-30 | -8.37% |
| 2024-06-30 | 1.57% |
| 2024-03-31 | -17.05% |
| 2023-12-31 | 19.18% |
| 2023-09-30 | -8.63% |
| 2023-06-30 | 0.73% |
| 2023-03-31 | -40.46% |
| 2022-12-31 | 5.56% |
| 2022-09-30 | -84.13% |
| 2022-06-30 | 34.42% |
| 2022-03-31 | -79.52% |
| 2021-12-31 | -96.89% |
| 2021-09-30 | -93.12% |
| 2021-06-30 | -132.86% |
| 2021-03-31 | -105.94% |
| 2020-12-31 | -137.00% |
| 2020-09-30 | -85.81% |
| 2020-06-30 | -182.15% |
| 2020-03-31 | -55.95% |
| 2019-12-31 | -122.50% |
| 2019-09-30 | -50.20% |
| 2019-06-30 | -49.44% |
| 2019-03-31 | -91.42% |
| 2018-12-31 | -147.62% |
| 2018-09-30 | -51.94% |
| 2018-06-30 | -72.65% |
| 2018-03-31 | -52.90% |
| 2017-12-31 | 13.24% |
| 2017-09-30 | -58.16% |
| 2017-06-30 | -77.20% |
| 2017-03-31 | -214.89% |
| 2016-12-31 | -2470.36% |
